The FDA's Category 2 list restricted 19 peptides from compounding. Now, approximately 14 of them may be coming back. HHS has signaled that peptides previously barred from compounding spanning categories like FDA Tracker for Cell and Gene Therapies in 2026 Alliance for Regenerative Medicine posted on the topic LinkedIn The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Peptide Reclassification 2026: What It Means for Providers